Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by GRAMPS1996on Nov 10, 2016 10:24am
195 Views
Post# 25444507

Frost

Frost

Opko Health CEO Adds Another 10,000 Shares To His Stake

OPK

One CEO is notably a long-time, frequent buyer of his company's shares. His most recent purchase was another 10,000 shares. Insider buying can be seen as a good sign for investors.

For well more than a year, the CEO of Opko Health Inc. (NASDAQ: OPK) has frequently bought shares of the biotech company. Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason: They believe the stock price will rise, and they want to profit from it. So, insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.

Phillip Frost, board chair as well as chief executive at this Miami-based company, has bought another 10,000 shares. The share price for that purchase was $9.36, for a total of more than $93,500. So far this month, he has acquired almost $890,000 worth of Opko shares, bringing his stake to more than 160.26 million shares. Opko has around 550.38 million shares outstanding.

Opko has a market capitalization of more than $5 billion but does not offer a dividend. It is one of the most shorted Nasdaq stocks, with 22.2 percent of the float sold short. Shares have retreated more than 12 percent in the past month, closing recently at $9.41, still near the CEO's latest purchase price. The stock is down less than 6 percent year-to-date.


Bullboard Posts